Evidence map›Paper›PMID 32067048›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study.

Karina A Top, Wendy Vaudry, Shaun K Morris, Anne Pham-Huy, Jeffrey M Pernica, Bruce Tapiéro, Soren Gantt, Victoria E Price, S Rod Rassekh, Lillian Sung and 4 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02447718 (Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02447718 phase4completednot on this map

Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study

TypeinterventionalSponsorCanadian Immunization Research NetworkRan2015 to 2018Enrolled156ConditionsAcute Lymphoblastic LeukemiaArmsPrevnar®13, Pneumovax® 23, Pediacel®
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

Karina A TopDepartments of Pediatrics and Community Health & Epidemiology, and the Canadian Center for Vaccinology, Dalhousie University and the IWK Health Centre, Halifax, Nova Scotia, Canada.
Wendy VaudryStollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada.
Shaun K MorrisHospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Anne Pham-HuyChildren's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada.
Jeffrey M PernicaDepartment of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
Bruce TapiéroCentre Hospitalier Universitaire de Ste-Justine, University of Montreal, Montreal, Quebec, Canada.
Soren GanttVaccine Evaluation Centre, British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
Victoria E PriceDepartment of Pediatrics, Dalhousie University and IWK Health Centre, Halifax, Nova Scotia, Canada.
S Rod RassekhBritish Columbia, Children's Hospital, Vancouver, British Columbia, Canada.
Lillian SungHospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Athena McConnellRoyal University Hospital, Saskatoon, Saskatchewan, Canada.
Earl RubinMcGill University Health Centre, Montreal, Quebec, Canada.
Rupesh ChawlaAlberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
Scott A HalperinDepartments of Pediatrics and Microbiology & Immunology and the Canadian Center for Vaccinology, Dalhousie University, and the IWK Health Centre, Halifax, Nova Scotia, Canada.
Dalhousie University · CABritish Columbia Children's Hospital · CAHospital for Sick Children · CAMcGill University Health Centre · CAMcMaster University · CARoyal University Hospital · CAUniversité de Montréal · CAUniversity of Alberta · CAUniversity of Calgary · CAUniversity of Ottawa · CA

Funding

CIHR CNF-151944
6 · The paper itself

Abstract

backgroundThere is no uniform guideline for postchemotherapy vaccination of children with acute lymphoblastic leukemia (ALL). We evaluated waning immunity to 14 pneumococcal serotypes, pertussis toxin (PT), tetanus toxoid (TT) and varicella, and immunogenicity of postchemotherapy diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) and pneumococcal vaccination among previously vaccinated children treated for ALL.

methodsThis was a multicenter trial of children with ALL enrolled 4-12 months postchemotherapy completion. Exclusion criteria included: infant ALL, relapsed ALL, and stem cell transplant recipients. Immunocompetent children were recruited as controls. Postchemotherapy participants received DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months later. Serology was measured at baseline, 2 and 12 months postvaccination. Adverse events were captured via surveys.

resultsAt enrollment, postchemotherapy participants (n = 74) were less likely than controls (n = 78) to be age-appropriately immunized with DTaP (41% vs 89%, P < .001) and PCV (59% vs 79%, P = .008). Geometric mean concentrations (GMCs) to TT, PT, PCV serotypes, and varicella were lower in postchemotherapy participants than controls after adjusting for previous vaccine doses (P < .001). Two months postvaccination, GMCs to TT, PT, and PCV serotypes increased from baseline (P < .001 for all antigens) and remained elevated at 12 months postvaccination. Antibody levels to PPV23 serotypes also increased postvaccination (P < .001). No serious adverse events were reported.

conclusionsChildren treated for ALL had lower antibody levels than controls against pneumococcal serotypes, tetanus, pertussis, and varicella despite previous vaccination. Postchemotherapy vaccination with DTaP-IPV-Hib, PCV13, and PPV23 was immunogenic and well tolerated. Children with ALL would benefit from systematic revaccination postchemotherapy. CLINICAL TRIALS REGISTRATION: NCT02447718.

Indexed as

Haemophilus VaccinesPrecursor Cell Lymphoblastic Leukemia-LymphomaAntibodies, BacterialCanadaChildDiphtheria-Tetanus-Pertussis VaccineHepatitis B VaccinesHumansInfantPoliovirus Vaccine, InactivatedVaccinationVaccines, CombinedVaccines, ConjugateAntibodies, BacterialDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesHepatitis B VaccinesPoliovirus Vaccine, InactivatedVaccines, CombinedVaccines, Conjugatechemotherapyimmunizationimmunosuppressionvaccination

Identifiers

PMID32067048
PMCPMC7713683
OpenAlexW3008135363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.